Simultaneous determination of granisetron and 7-hydroxygranisetron in human plasma by high-performance liquid chromatography with fluorescence detection.
A highly sensitive high-performance liquid chromatographic method for the determination of granisetron, a novel antiemetic agent for cancer therapy, and its pharmacologically active and major metabolite in human plasma is described. Methylation of the metabolite with trimethylsilyldiazomethane was employed for sample pretreatment. As a result of this treatment, the originally non-fluorescent metabolite could be detected simultaneously with granisetron using fluorescence detection. Both the compounds and the internal standard added were isocratically well resolved from endogenous peaks in plasma on an ODS column. The concentrations of the compounds were proportional to the peak-area ratios over the practical determination ranges of 0.2-100 ng/ml for granisetron and 0.1-50 ng/ml for the metabolite. In tests, reproducibilities for granisetron at 1 ng/ml and the metabolite at 0.5 ng/ml as determined by the relative standard deviation (n = 3) were less than 3.98 and 7.23%, respectively, in a single run.
Kudoh
S
S
Takasaki-Laboratory of SmithKline Beecham Seiyaku, Gunma, Japan.
Sato
T
T
Okada
H
H
Kumakura
H
H
Nakamura
H
H
D002851:Chromatography, High Pressure Liquid; D003978:Diazomethane / Q000031:analogs & derivatives; D017829:Granisetron / Q000031:analogs & derivatives* / Q000097:blood*; D006801:Humans; D007202:Indicators and Reagents; D000432:Methanol / Q000737:chemistry; D008745:Methylation; D013050:Spectrometry, Fluorescence; D014297:Trimethylsilyl Compounds
D003978:Diazomethane; D017829:Granisetron; D007202:Indicators and Reagents; D000432:Methanol; D014297:Trimethylsilyl Compounds; C092106:7-hydroxygranisetron; C060070:trimethylsilyldiazomethane